title: [Gynecology/Obstetrics. Magnesium sulfate for fetal neuroprotection in preterm delivery. Latest advances in contraception.].
abstract: Morbidity of neonates born before 32 weeks remains significant. Cerebral palsy is found in up to 8 to 10% of survivors. Three randomized controlled trials evaluated the effectiveness of magnesium sulphate given to mothers with a risk of imminent very preterm delivery to prevent perinatal death or cerebral palsy in children. These studies suggest a reduction of the risk of cerebral palsy by magnesium sulphate from 6.5% to 4.8% (relative risk 0.71, 95% CI 0.55-0.91). These results remain controversial, but warrant information to the parents and the implementation of treatments protocols for selected cases.
authors.affiliation: Département de gynécologie et d'obstétrique, HUG, Genève. olivier.irion@hcuge.ch
authors.forename: Olivier
authors.initials: O
authors.lastname: Irion
authors.forename: Olivier
authors.initials: O
authors.lastname: Julen
authors.forename: J B
authors.initials: JB
authors.lastname: Dubuisson
authors.forename: Michal
authors.initials: M
authors.lastname: Yaron
authors.forename: A Godinho
authors.initials: AG
authors.lastname: Lourenço
mesh_terms: D002547:Cerebral Palsy / Q000517:prevention & control*; D003271:Contraceptive Agents, Female; D005260:Female; D006801:Humans; D008278:Magnesium Sulfate / Q000627:therapeutic use*; D011247:Pregnancy; D047928:Premature Birth; D015149:Tocolytic Agents / Q000627:therapeutic use*
chemical_list: D003271:Contraceptive Agents, Female; D015149:Tocolytic Agents; D008278:Magnesium Sulfate